Beta-2-containing nicotinic acetylcholine receptor (β2-nAChR) (β2-nAChR)

The beta-2-containing nicotinic acetylcholine receptor (β2-nAChR) is a subtype of pentameric ligand-gated ion channel primarily located in the central nervous system [1]. It is defined by the inclusion of the β2 subunit, encoded by the CHRNB2 gene, which most frequently partners with the α4 subunit to form the α4β2 heteropentamer [2]. This specific configuration represents the most abundant high-affinity nicotinic receptor in the human brain and is a key mediator of the effects of nicotine [3]. These receptors play a pivotal role in modulating neuronal excitability and the release of various neurotransmitters, including dopamine, GABA, and glutamate [3]. By regulating these neurotransmitters, β2-nAChRs influence critical functions such as reward processing, attention, and memory [4]. Clinically, the receptor is the primary target for smoking cessation aids like varenicline, which acts as a partial agonist to reduce withdrawal symptoms and reward [4]. Mutations in the CHRNB2 gene are linked to autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), highlighting its role in maintaining excitatory-inhibitory balance [5]. Furthermore, a significant reduction in β2-nAChR density is observed in neurodegenerative conditions like Alzheimer's and Parkinson's diseases, contributing to cognitive decline [2]. Therapeutic research continues to explore β2-nAChR modulators for treating depression, pain, and cognitive impairment [5].

Other names

Neuronal acetylcholine receptor subunit beta-2CHRNB2Cholinergic receptor nicotinic beta 2 subunitnACHRB2

Drugs targeting this receptor act as agonists, partial agonists, or antagonists to modulate the opening of the cation-selective pore, thereby regulating neuronal depolarization and the subsequent release of neurotransmitters like dopamine [3, 4].